Frankfurt - Delayed Quote EUR

Beximco Pharmaceuticals Limited (R2WA.F)

Compare
0.2760 +0.0100 (+3.76%)
As of 8:20 AM GMT+2. Market Open.
Loading Chart for R2WA.F
DELL
  • Previous Close 0.2660
  • Open 0.2760
  • Bid 0.2680 x 3669800
  • Ask 0.3460 x 3183100
  • Day's Range 0.2760 - 0.2760
  • 52 Week Range 0.2360 - 0.5200
  • Volume 413,000
  • Avg. Volume 7,999
  • Market Cap (intraday) 138.845M
  • Beta (5Y Monthly) 0.64
  • PE Ratio (TTM) 3.07
  • EPS (TTM) 0.0900
  • Earnings Date Oct 30, 2024 - Nov 4, 2024
  • Forward Dividend & Yield 0.03 (11.08%)
  • Ex-Dividend Date Nov 10, 2023
  • 1y Target Est --

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

www.beximcopharma.com

5,500

Full Time Employees

June 30

Fiscal Year Ends

Recent News: R2WA.F

View More

Performance Overview: R2WA.F

Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

R2WA.F
37.27%
MSCI WORLD
17.00%

1-Year Return

R2WA.F
28.86%
MSCI WORLD
29.95%

3-Year Return

R2WA.F
70.43%
MSCI WORLD
22.42%

5-Year Return

R2WA.F
0.89%
MSCI WORLD
0.00%

Compare To: R2WA.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: R2WA.F

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    234.95M

  • Enterprise Value

    279.77M

  • Trailing P/E

    3.02

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.37

  • Price/Book (mrq)

    0.35

  • Enterprise Value/Revenue

    0.88

  • Enterprise Value/EBITDA

    4.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.37%

  • Return on Assets (ttm)

    6.97%

  • Return on Equity (ttm)

    10.99%

  • Revenue (ttm)

    43.08B

  • Net Income Avi to Common (ttm)

    5.33B

  • Diluted EPS (ttm)

    0.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.73B

  • Total Debt/Equity (mrq)

    14.73%

  • Levered Free Cash Flow (ttm)

    4.42B

Research Analysis: R2WA.F

View More

Company Insights: R2WA.F

Research Reports: R2WA.F

View More

People Also Watch